Perspective Therapeutics (CATX) Gross Profit (2010 - 2023)

Perspective Therapeutics has disclosed Gross Profit across 14 years of filings, most recently posting -$39000.0 for Q4 2023.

• Gross Profit for Q4 2023 came in at -$39000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2023 was $1.4 million (down 48.44% YoY), and the FY2023 annual result was $1.4 million, changed N/A from the prior year.
• Gross Profit came in at -$39000.0 for Q4 2023 at Perspective Therapeutics, down from $738000.0 in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $1.7 million in Q1 2020 to a low of -$39000.0 in Q4 2023.
• The 5-year median for Gross Profit is $1.1 million (2020), against an average of $971947.4.
• Across the five-year window, Gross Profit jumped 135.88% in 2019 and sank 73.22% in 2023, its largest moves.
• Perspective Therapeutics' Gross Profit stood at $1.1 million in 2019, then climbed by 5.04% to $1.2 million in 2020, then gained by 4.54% to $1.2 million in 2021, then sank by 66.07% to $414000.0 in 2022, then plunged by 109.42% to -$39000.0 in 2023.
• The last three Gross Profit figures came in at -$39000.0 (Q4 2023), $738000.0 (Q3 2023), and $248000.0 (Q2 2023), per Business Quant data.